NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP
Apyx Medical Corporation APYX
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$52.8M
▲ 9.9% vs FY2024
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-78.0%
Net margin · FY25
-21.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 52.8M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 21 cents on every revenue dollar this year.
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-78.0%
Return on equity, FY2025
ROE
Operating margin-12.2%
Net margin-21.2%
Return on assets-17.0%
Each USD of equity lost 78 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+13.8% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+5.9%
+13.8%
+6.0%
+5.3%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.04B
Shares outstanding, FY2025
Change, 5 years+21.9%
Change, 10 years+54.5%
The share count grew 22% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 66.8M
total assets, end of FY2025
Total assetsUSD 66.8M
EquityUSD 14.5M
CashUSD 31.7M
Gross debtUSD 34.8M
Net debtUSD 3.1M
Current ratio5.00×
Net debt stands at 21% of equity.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.1
0.0
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
0.0
Income tax $B
0.0
0.0
−0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
0.0
−0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.1
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
0.0
EPS, diluted $
·
·
−0.54
−0.67
−0.44
−0.35
−0.58
1.83
−0.17
−0.15
0.24
−1.03
−0.40
0.03
0.01
−0.09
0.03
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−78.0
−114.7
−58.2
−50.8
−25.8
−17.6
−24.9
114.9
−21.0
−46.5
−43.1
−168.0
−20.7
2.7
0.5
−7.2
2.8
Shares out B
0.04
0.04
0.03
0.03
0.03
0.03
0.03
0.03
0.03
0.03
0.03
0.02
0.02
0.02
0.02
17.56
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
66 of 66
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed